Syntrix Biosystems, Inc.
CXCR1/2 inhibitor molecule for myelodysplastic syndrome treatment
- Sector
- Biotech
- Headquarters
- Auburn, WA
- Total capital
- $17.7M
- Federal grants
- $17.7M
- 21 awards · 2015–2025
- Rank in peer group#9 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 18
- 13 pending · first 2015
- Rank in peer group#13 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$904K
- Federal grantHealth and Human S · Phase II · A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients$627K
- Federal grantHealth and Human S · Phase II · A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients$400K
- Federal grantHealth and Human S · Phase II · A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$745K
- Federal grantHealth and Human S · Phase II · A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$400K
- Federal grantHealth and Human S · Phase II · A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$651K
- Federal grantHealth and Human S · Phase II · A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$80K
Show 14 earlier federal awards
- Federal grantHealth and Human S · Phase II · HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$1.6M
- Federal grantHealth and Human S · Phase II · A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$223K
- Federal grantHealth and Human S · Phase II · A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$1.2M
- Federal grantHealth and Human S · Phase II · HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$3M
- Federal grantHealth and Human S · Phase II · A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$204K
- Federal grantHealth and Human S · Phase II · HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$398K
- Federal grantHealth and Human S · Phase II · Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$977K
- Federal grantHealth and Human S · Phase II · A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$2M
- Federal grantHealth and Human S · Phase II · Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$998K
- Federal grantHealth and Human S · Phase II · Phase II clinical evaluation of Omnitram in neuropathic pain$657K
- Federal grantHealth and Human S · Phase II · A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$621K
- Federal grantHealth and Human S · Phase II · Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$990K
- Federal grantHealth and Human S · Phase II · Phase II clinical evaluation of Omnitram in neuropathic pain$843K
- Federal grantHealth and Human S · Phase II · Phase II clinical evaluation of Omnitram in neuropathic pain$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#9 · top 2%
- Granted patents#13 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 18 granted of 31- GrantedTreating Pain Using DesmetramadolUSPTOUS 11,000,488
- GrantedAminopyrimidinecarboxamides As CXCR2 ModulatorsUSPTOUS RE48,547
- GrantedMethod For Treating Cancer Using Chemokine AntagonistsUSPTOUS 10,993,953
Show all 31 patent records
- Treating Pain Using DesmetramadolMay 11, 2021 · US 11,000,488Granted
- Aminopyrimidinecarboxamides As CXCR2 ModulatorsMay 11, 2021 · US RE48,547Granted
- Method For Treating Cancer Using Chemokine AntagonistsMay 4, 2021 · US 10,993,953Granted
- Method For Treating Cancer Using Chemokine AntagonistsMay 26, 2020 · US 10,660,909Granted
- Method For Treating Cancer Using Dual Antagonists Of CXCR1 And CXCR2Feb 18, 2020 · US 10,561,676Granted
- Aminopyridinecarboxamides as CXCR2 ModulatorsNov 26, 2019 · US RE47,740Granted
- Pyrimidinecarboxamides As CXCR2 ModulatorsJun 4, 2019 · US RE47,415Granted
- Pyridinecarboxamides As CXCR2 ModulatorsMar 5, 2019 · US RE47,267Granted
- Use Of Thiopyrimidinecarboxamide For Treating CancerNov 20, 2018 · US 10,130,645Granted
- Method For Treating Cancer Using Chemokine AntagonistsAug 14, 2018 · US 10,046,002Granted
- Methods For Overcoming Resistance To TramadolNov 9, 2017 · Application 15662160Pending
- Compositions For Overcoming Resistance To TramadolNov 9, 2017 · Application 15662189Pending
- Methods for Overcoming Resistance to TramadolNov 7, 2017 · US 9,808,432Granted
- Compositions For Overcoming Resistance To TramadolAug 1, 2017 · US 9,717,701Granted
- Methods for Overcoming Resistance to TramadolAug 1, 2017 · US 9,717,700Granted
- Use Of Thiopyrimidinecarboxamide For Treating CancerJul 18, 2017 · US 9,707,248Granted
- Thiopyrimidinecarboxamide For Use In Treating Pulmonary DiseaseNov 1, 2016 · US 9,480,694Granted
- Aminopyrimidinecarboxamides as CXCR2 ModulatorsMar 31, 2015 · US 8,993,541Granted
- Pyrimidinecarboxamides As CXCR2 ModulatorsMar 17, 2015 · US 8,981,106Granted
- Thiopyrimidinecarboxamides As CXCR1/2 ModulatorsMar 3, 2015 · US 8,969,365Granted
- Treatment Of Antifolate NeurotoxicityJun 19, 2014 · Application 13905044Pending
- Aminopterin Dosage Forms And Methods For Inflammatory DisordersApplication PCTUS2006008233Pending
- Combination Therapy For Treating Hematologic MalignanciesApplication 63564132Pending
- Treating Pain Using DesmetramadolApplication PCTUS2019039186Pending
- Method For Treating Cancer Using Chemokine AntagonistsApplication PCTUS2019019305Pending
- Method For Treating Cancer Using Chemokine AntagonistsApplication 15354838Pending
- Thiopyrimidinecarboxamides As CXCR1/2 ModulatorsApplication PCTUS2013053376Pending
- Compositions And Methods For Overcoming Resistance To TramadolApplication PCTUS2012045885Pending
- Aminopyridine- And Aminopyrimidinecarboxamides As CXCR2 ModulatorsApplication PCTUS2011048668Pending
- Pharmaceutical Composition Comprising Racemic AminopterinApplication PCTUS2010021899Pending
- Method For Increasing Survival In Patients With CancerApplication PCTUS2025019459Pending
Related companies, and why
- ELSOHLY LABORATORIES, INC.Similar federal contract value in Biotech · null in contracts
- True North TherapeuticsSimilar federal contract value in Biotech · null in contracts
- AJK BIOPHARMACEUTICAL LLCSimilar federal contract value in Biotech · null in contracts
- ByHeart, Inc.Similar federal contract value in Biotech · null in contracts
- Venomyx, Inc.Similar federal contract value in Biotech · null in contracts
- N'WAII INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .